SARS-CoV-2 - Clevudine - Therapeutic Candidates

SARS-CoV-2 - Clevudine - Therapeutic Candidates


Clevudine, marketed as Levovir and Revovir, is a synthetic pyrimidine analogue. It is an antiviral drug used in the treatment of hepatitis B. In cells, clevudine is phosphorylated into its active metabolites, clevudine monophosphate and clevudine triphosphate. The triphosphate metabolite competes with thymidine for incorporation into viral DNA, causing DNA chain termination and inhibiting the function of the hepatitis B virus (HBV) DNA polymerase (reverse transcriptase). Clevudine has a long half-life and exhibits a significant reduction in covalently closed circular DNA (cDNA), so that the patient is less likely to relapse after cessation of treatment.
A study is currently underway to evaluate the safety and efficacy of clevudine in patients with a moderate form of COVID-19 caused by CoV-2 SARS. In this Phase 2 study, clevudine is combined with hydroxychloroquine.

Search result : 78 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 10
  • Biochemicals 68
  • Inhibitor/Antagonist/Agonist 7
  • RNAi 3
  • virus 2
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
orb1889872-25mg
 25mg 
orb1226015-5mg
 5mg 
orb1300762-25mg
 25mg 
orb1300762-10mg
 10mg 
orb1889871-50mg
 50mg 
orb1226015-50mg
 50mg 
orb1227508-50mg
 50mg 
orb1300762-2mg
 2mg 
orb1300762-50mg
 50mg 
orb1889873-100mg
 100mg 
orb1889874-10mg
 10mg 
orb1226015-100mg
 100mg 
orb1300762-5mg
 5mg 
orb1226015-10mg
 10mg 
orb1226015-25mg
 25mg 
orb1226015-2mg
 2mg 
orb1300762-100mg
 100mg 
orb134390-250mg
 250mg 
orb134390-1g
 1g 
orb134390-100mg
 100mg